Arvinas Obtains $19,250,000 Series A Financing Round

  • Feed Type
  • Date
  • Company Name
  • Mailing Address
    395 Winchester Ave New Haven, CT 06511
  • Company Description
    Arvinas is a pharmaceutical company focused on developing new small molecule strategies aimed at removing unwanted cellular proteins. We are translating these innovative protein degradation approaches into novel drugs for the treatment of cancer and other diseases.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
    Series A
  • Proceeds Purposes
    The funds will support the development of the company’s technology which has primary application in multiple oncology indications and potential in inflammatory, autoimmune and rare diseases.
  • M&A Terms
  • Venture Investor
    Canaan Partners
  • Venture Investor
    5AM Ventures
  • Venture Investor
    Connecticut Innovations
  • Venture Investor
    Elm Street Ventures

Trending on Xconomy